Any current/future capex/capital investment/strategic investment?

Healthcare Triangle plans an IPO to raise around $20-25 million for growth in the US healthcare space. The IPO capital will support operational and future investment needs for the next 2-3 years. The company has made significant investments in product and platform development, including DataEZ and Cloud Art (IAM and multifactor authentication). Investments are focused on building recurring revenue models and platform-based offerings to improve margins. There is ongoing R&D investment alongside sales and marketing spends to support growth. The company aims to improve offshore delivery capabilit

Future growth expectations in sales/revenue/volumes?

Revenue expected to be stable over the next two quarters with accelerated growth beginning next financial year due to investments in sales and marketing. Anticipated 20% topline year-after-year growth over time, driven by recovery in hospital business and growth in platform offerings like DataEZ. Hospital business expected to return to pre-COVID levels within 1-2 quarters, contributing an increase of about Rs 10 Crores quarterly. Focus on recurring revenue models and multiyear platform deals to improve growth and valuation. Expansion into EMR implementation and AI-powered DocuRoute to drive fu

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth of 20% year-over-year expected over time, with hospital business recovering post-COVID (Page 18, 7). Gross margins currently at 36%; targeted increase to 50% over next 4-6 quarters by focusing on recurring revenue platforms and offshore delivery (Page 18). Long-term plan for DataEZ platform to generate 75% gross margins within 3-4 years, contributing to overall margin expansion (Page 18). EBITDA margin historical range was 30-35%; future margins expected to be lower if R&D capitalization ceases, but improvements anticipated via recurring revenues and cost optimization (Page 17,

Current/ Expected Orderbook/ Pending Orders?

The company plans to provide more clarity on the order pipeline in future investor communications. Currently, detailed order book or pending orders figures are not explicitly disclosed in the transcript. Suresh Venkatachari emphasized improved communication and transparency in future quarters regarding order pipeline. Investments in sales and marketing in both US and India are expected to accelerate new order inflow. The company is focusing on hospital business recovery and growth in Life Sciences and Pharma, likely impacting order book positively. DataEZ platform is generating recurring reven

SecureKloud TechQ2 FY21IT - Services

SecureKloud Tech Q2 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹15.02Market Cap: ₹50 CrSector: IT - Services

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 3

Revenue expected to be stable over the next two quarters with accelerated growth beginning next financial year due to investments in sales and marketing.
Anticipated 20% topline year-after-year growth over time, driven by recovery in hospital business and growth in platform offerings like DataEZ.
Hospital business expected to return to pre-COVID levels within 1-2 quarters, contributing an increase of about Rs 10 Crores quarterly.
Focus on recurring revenue models and multiyear platform deals to improve growth and valuation.
Expansion into EMR implementation and AI-powered DocuRoute to drive future revenue streams.
Offshore delivery model expansion planned to improve margins and cost efficiency, facilitating growth.
IPO plans for Healthcare Triangle US subsidiary expected to enhance valuation and support growth capital.

Margin guidance

Category 1

Revenue growth of 20% year-over-year expected over time, with hospital business recovering post-COVID (Page 18, 7).
Gross margins currently at 36%; targeted increase to 50% over next 4-6 quarters by focusing on recurring revenue platforms and offshore delivery (Page 18).
Long-term plan for DataEZ platform to generate 75% gross margins within 3-4 years, contributing to overall margin expansion (Page 18).
EBITDA margin historical range was 30-35%; future margins expected to be lower if R&D capitalization ceases, but improvements anticipated via recurring revenues and cost optimization (Page 17, 18).
Investment in sales and marketing to accelerate revenue growth starting next financial year (Page 7, 8).
Recurring platform revenues to grow, enhancing profitability and valuation multiples (Page 17).
Overall operating profits expected to improve with margin expansion and rising recurring revenue streams through platform growth and offshore efficiencies.

See what SecureKloud Tech management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

- Healthcare Triangle (HTI), the US subsidiary of 8K Miles, is planning an IPO to raise approximately $20-25 million, anticipated before mid-next year (Page 8, 15). - The IPO proceeds will support growth in the US healthcare space over the next 2-3 years (Page 11). - There is investor permission to raise up to $50 million initially targeting $20-25 million through the IPO (Page 15). - Current debt stands at about Rs 138 Crores, primarily promoter debt; no new immediate debt plans stated, but the HTI IPO proceeds will help retire Indian loans by shifting billing from India to HTI (Page 11, 12). - No explicit mention of additional debt fundraising in the near term; focus appears to be on equity fundraising through the HTI IPO (Page 11). In summary, the main future fundraising effort is the planned $20-25 million IPO for Healthcare Triangle, aimed at equity capital for growth and debt retirement.

Order book

Yes

The company plans to provide more clarity on the order pipeline in future investor communications.
Currently, detailed order book or pending orders figures are not explicitly disclosed in the transcript.
Suresh Venkatachari emphasized improved communication and transparency in future quarters regarding order pipeline.
Investments in sales and marketing in both US and India are expected to accelerate new order inflow.
The company is focusing on hospital business recovery and growth in Life Sciences and Pharma, likely impacting order book positively.
DataEZ platform is generating recurring revenue backed by a $2 million/year managed services contract.
Overall, they expect a stable revenue in the near term and accelerated revenue growth from the next financial year driven by platform and recurring business.

See what SecureKloud Tech management said on order book — free account, 30 seconds.

Capex plans

Yes

Healthcare Triangle plans an IPO to raise around $20-25 million for growth in the US healthcare space.
The IPO capital will support operational and future investment needs for the next 2-3 years.
The company has made significant investments in product and platform development, including DataEZ and Cloud Art (IAM and multifactor authentication).
Investments are focused on building recurring revenue models and platform-based offerings to improve margins.
There is ongoing R&D investment alongside sales and marketing spends to support growth.
The company aims to improve offshore delivery capabilities to enhance margins.
Some future announcements on new technology, especially in security and blockchain platforms, are expected in the next quarters.
No specific details on incremental capex amount but strategic investments in technology platforms and IPO fundraising are key focus areas.

Track SecureKloud Tech — get its next earnings analysis in your feed

How does SecureKloud Tech rank vs peers in IT - Services?

Pro feature

ThisSecureKloud Tech

Rev 3Mar 1

See where SecureKloud Tech sits in IT - ServicesSee which companies these are, and every other name in the sector.Open rankings

How does SecureKloud Tech rank in IT - Services?

Compare SecureKloud Tech against every IT - Services company (Q2 FY21) on revenue, margins and earnings-call signals.

View IT - Services leaderboard →

What SecureKloud Tech's management said in earlier quarters

Earlier calls (4)

Others in IT - Services this season

Intense Technologies (Q2 FY27)
Standalone: ₹1,203.75 Lakhs . Key results statement takeaways from Intense Technologies Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Quadpro ITeS (Q2 FY27)
This reflects a year-on-year decline in quarterly revenue of approximately 7.4%. Key results statement takeaways from Quadpro ITeS Ltd's Q2 FY27 results stateme
Inspirisys Solutions (Q2 FY27)
For the quarter ended September 30, 2026, the consolidated revenue from operations was ₹11,978 lakhs (page 10). Key results statement takeaways from Inspirisys
Synoptics Techno (Q2 FY27)
Revenue (Net Sales/Income from Operations) for half year ended Sept 30, 2026: ₹4,447.08 lakhs (consolidated), ₹4,444.96 lakhs (standalone). Key results statemen

Compare:vs L&T Technology vs Inventurus Knowl vs Tata Technologies

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →